MedPath

bivalirudin

These highlights do not include all the information needed to use BIVALIRUDIN FOR INJECTION safely and effectively. See full prescribing information for BIVALIRUDIN FOR INJECTION. Initial U.S. Approval: 2000

Approved
Approval ID

5d9a45c6-e234-4d56-9132-5e24e65852e6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 9, 2021

Manufacturers
FDA

Slate Run Pharmaceuticals, LLC

DUNS: 039452765

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

bivalirudin

PRODUCT DETAILS

NDC Product Code70436-025
Application NumberANDA213078
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateJune 9, 2021
Generic Namebivalirudin

INGREDIENTS (3)

MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
BIVALIRUDINActive
Quantity: 250 mg in 1 1
Code: TN9BEX005G
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

bivalirudin - FDA Drug Approval Details